Drugs / RTS,S/AS02D
last change Jan 2013 re-read 2 minutes ago

RTS,S/AS02D

Vaccine

Developed for
malaria
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00289185 Sep 2006 → Feb 2008 malaria GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as RTS,S/AS02(D) “Safety, immunogenicity and efficacy of the RTS,S/AS02(D) vaccine candidate when integrated into a standard EPI schedule for infants have been reported over a nine-month...” PMID 23297680 Jan 2013
1

NCT00289185

Modality Vaccine “RTS,S/AS02D, a Candidate Malaria VaccineNCT00289185